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COVID-19
In December 2019, severe acute respiratory syndrome coronavirus 2 
(SARS-CoV-2) was identified as the pathogen responsible for a series of 
cases of pneumonia in the Chinese province of Hubei, Wuhan.1 This 
became known as coronavirus disease 2019 (COVID-19). On 11 March 
2020, the WHO declared COVID-19 a pandemic after numerous cases 
and deaths in more than 100 different countries.2 Globally, as of 
7 February 2021, confirmed cases reached 105,394,301 (35,481,004 in 
Europe) with 2,302,302 deaths.3
The activation of the surface spike protein of SARS-CoV-2 allows it to bind 
to the human angiotensin-converting enzyme 2 (ACE2) receptor. ACE2 is 
expressed in the lung and appears the main site of entry for the virus.4 
ACE2 is also expressed in the heart, vascular endothelium, kidneys and 
intestinal epithelium, thus providing a potential mechanism for the 
multiorgan effects of COVID-19.5,6 
The main symptoms of COVID-19 are fever, a new persistent cough and a 
loss or change to sense of smell or taste.7 There is a long list of other 
reported symptoms, including myalgia and diarrhoea.8
Cardiovascular manifestations of COVID-19 include MI, heart failure and 
myocarditis (Figure 1).9–15 Baseline blood tests and common cardiac 
investigations will help to diagnose these pathologies. Under initial 
lockdown measures, elite sports were halted but as the pandemic has 
progressed and plans are made for a ‘new normal’, consensus 
recommendations for cardiac assessment of athletes who may be 
affected by COVID-19 have been proposed.16–22 The consensus 
recommendations and preparticipation screening commonly involve an 
ECG and some also recommend an echocardiogram.
Athletic training regimens can often exceed ‘normal’ physical limits and if 
continued, cardiovascular adaptation to exercise can occur. These cardiac 
changes, known as athlete’s heart (AH) may manifest on investigations 
such as the ECG or echocardiogram and can mimic mild phenotypes of 
cardiac pathology. As preparticipation sports screening in the COVID-19 
era becomes more routine, an understanding of how to differentiate 
physiological adaptation from pathological change in athletes will aid 
clinical decision-making.
The objectives of this review are to:
• Describe the main cardiovascular manifestations of COVID-19.
• To discuss the potential overlap – or the ‘grey zone’ – where 
physiological adaptation due to AH may overlap with mild 
pathological change.
• Summarise recent consensus algorithms for the cardiac 
assessment of athletes who may have been affected by  
COVID-19.
• Highlight international recommendations for the management of 
athletes with cardiac pathology related to COVID-19.
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Severity and General Clinical 
Manifestations of COVID-19
When assessing athletes with a current or past history of COVID-19, it is 
important to consider individual demographics and comorbidities which 
have been shown to confer worse outcomes. It is less likely that younger 
athletes will have the same risk profile associated with COVID-19 as 
masters athletes (aged >35 years). While severe illness due to COVID-19 
can occur in healthy people irrespective of age, it predominantly occurs 
with advancing age and in those with multiple comorbidities. Adults of 
middle and older age are most commonly affected. Studies with 
hospitalised cohorts have shown that 74–86% are at least 50 years old.1 
Advanced age is also associated with increased mortality from 
COVID-19.23 
Ethnicity also plays an important role in prognosis. Death rates in the UK 
from COVID-19 among people from black, Asian and minority ethnic 
(BAME) backgrounds have been shown to be higher 
than their white counterparts.24 In addition, a systematic review has 
shown that BAME people are at higher risk of acquiring the virus.25 
Comorbidities associated with severe COVID-19 illness and mortality 
include pre-existing cardiovascular disease, diabetes, hypertension, 
malignancy, chronic lung disease, smoking, obesity and chronic kidney 
disease.11
General clinical manifestations of COVID-19 from large registry data 
include: cough (50%), fever (43%), myalgia (36%), headache (34%), 
dyspnoea (29%), sore throat (20%), diarrhoea (19%) and nausea/vomiting 
(12%). Loss of smell or taste, abdominal pain and rhinorrhoea were 
reported in fewer than 10% of cases each.26 With specific reference to 
athletes, symptoms of breathlessness disproportionate to the level of 
exercise should prompt a cardiovascular assessment.
There is a wide spectrum of illness as reported by the Chinese Center for 
Disease Control and Prevention.27 This ranges from mild disease, with no 
symptoms or mild pneumonia, in 81% of the cohort; severe disease – such 
as dyspnoea, hypoxia and significant lung changes on imaging – in 14% of 
the cohort; critical disease – such as shock, respiratory failure, multiorgan 
failure – in 5% of the cohort. Overall, the case fatality rate was 2.3% with 
no deaths reported in non-critical cases. 
Cardiac Manifestations of COVID-19 
The presence of myocardial injury is an important finding in those with 
COVID-19 and is associated with increased severity of illness as well as 
worse prognosis.12,28,29 Myocardial injury is defined as the elevation of 
high sensitivity cardiac troponin (hs-cTn) above the 99th percentile of 
normal or new echocardiographic/ECG abnormality.12 Ischaemic and non-
ischaemic aetiology of increased troponin levels are described below. 
MI
MI can occur as a result of systemic inflammatory response syndrome 
caused by severe viral infections. In COVID-19, severe inflammatory stress 
leads to a release of circulating cytokines. This may lead to plaque 
instability with higher risk of rupture and thrombus formation leading to 
acute coronary syndrome (type 1 acute MI).30
A type 2 MI due to a myocardial mismatch in oxygen demand and 
supply may also be a complication of viral infections. Hypoxaemia, 
vasoconstriction and the haemodynamic consequences of sepsis 
cause this mismatch which leads to myocardial ischaemia. The 
medical management of MI in the era of COVID-19 is through established 
pathways.31 
Heart Failure
Acute illness caused by COVID-19 may precipitate heart failure in those 
with pre-existing or undiagnosed heart disease or due to acute myocardial 
injury, such as coronary artery disease, stress cardiomyopathy and 
cytokine storm.11,15 
Cardiac Arrhythmias
Cardiac dysrhythmias can occur as a sequelae of a primary cardiac 
pathology, such as MI or a fibrotic substrate due to myocarditis and have 
also been reported in the setting of viral illness due to hypoxia, 
inflammatory stress and fever.11
Thromboembolism
Increased risk of thromboembolism in patients with COVID-19 has been 
reported with a variety of mechanisms postulated including immobility, 
hypercoagulable status, a propensity for disseminated intravascular 
coagulopathy and active inflammation.11,12
Myocarditis
Many viruses are able to bind directly to molecular targets in the 
myocardium to inflict damage via a range of mechanisms.30 Myocarditis is 
characterised by inflammatory infiltrates and myocardial injury in the 
absence of an ischaemic cause. Cases of COVID-19-related myocarditis 
have been reported, with some reviews suggesting that up to 7% of 
COVID-19 deaths were attributable to myocarditis.14,32 This may be an 
overestimate, as the clinical diagnosis in most cases is assumed rather 
than confirmed by myocardial biopsy. 
COVID-19 myocarditis may present with a variety of symptoms, including 
fatigue, chest discomfort or breathlessness. In athletes, symptoms such 
as fatigue may be more difficult to establish at an earlier stage due to 
confounding factors such as the return to full participation in sports after 
a reduced workload. 
Typical baseline investigations for those with suspected myocarditis 
include blood tests and ECG. Imaging investigations which may be 
undertaken include echocardiography and cardiac MRI (CMR). These main 
investigations are discussed below:33
Epidemiology
●     >105 million confirmed cases
●     >2.3 million deaths
●     >200 countries
Symptoms
●    Cough, fever, dyspnoea,
     loss of smell or taste
●    Myalgia, headache, sore
     throat
●     Abdominal pain,
     diarrhoea, vomiting
Risk factors
●    Older age
●    Cardiovascular disease
●    Diabetes
●    Hypertension
●    Chronic kidney disease
●    Obesity
●    Ethnicity: Black, Asian,











Figure 1: The Epidemiology, Symptoms, Risk Factors 
and Cardiovascular Complications of COVID-19
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• Blood tests: myocarditis often results in elevated levels of 
inflammatory markers, such as C-reactive protein. Baseline cardiac 
enzymes such as troponin and N-terminal pro-B-type natriuretic 
peptide (BNP) can also be elevated.11
• ECG: changes include ST elevation/depression, PR depression and 
T wave inversion (TWI). 
• Echocardiography: echocardiographic features which may be in 
keeping with myocarditis include the findings of pericardial effusion; 
ventricular dysfunction (global or regional wall motion abnormality 
and reduction in ejection fraction. Left ventricular (LV) hypertrophy 
has been reported in cases of acute myocarditis as a consequence of 
myocardial oedema.34
• CMR: an important imaging tool in the diagnosis and risk stratification 
of myocarditis. Late gadolinium enhancement allows detection of 
fibrosis and has been shown in studies to be an adverse predictor of 
mortality when present.35
Diagnostic Conundrum in Asymptomatic 
Athletes: The Grey Zone
An understanding of the ‘grey-zone’ overlap between physiological 
adaptation and pathology in certain cardiac investigations is important 
when assessing athletes regarding potential cardiovascular complications 
of COVID-19. This is particularly relevant during cardiac screening of 
athletes who have not had COVID-19 symptoms to try to reduce the 
misdiagnosis of cardiac pathology. Differentiating physiology from 
pathology with regards to the main investigations used in preparticipation 
screening is described below and summarised in Figure 2.
Troponin Levels 
A considerable proportion of patients hospitalised with COVID-19 have 
been found to have elevated troponin levels, with some reports finding 
this in up to 28% of affected cases.30 Care should be taken when 
interpreting troponin levels in asymptomatic athletes if they have recently 
participated in sport or training. 
Several studies have reported transient troponin elevation after 
marathons, triathlon events, cycling and other forms of physical activity. 
Exercise intensity and duration cannot reliably predict the magnitude of 
troponin release. Cardiac biomarker alterations have been described 
following table tennis games and prolonged walking.36 There are 
reports of troponin release beginning as early as 30 minutes into 
sustained endurance exercise which may represent a normal response 
to exercise.37–39
ECG
Repolarisation changes such as TWI may be associated with COVID-19-
related cardiovascular complications, such as myocarditis. However, 
athletic adaptation to exercise is associated with a number of ECG 
changes, which are also dependant on age, sex, ethnicity and sporting 
discipline.40–44 As a general rule men, black athletes and athletes 
participating in high endurance sport tend to exhibit more profound 
ECG changes. 
Studies assessing physiological ECG changes have shown that TWI can be 
normal in white athletes when seen in leads V1–V2.42,44 This is more 
commonly seen in women (4.3% versus 1.4% in men) and more prevalent 
in athletes when compared to healthy sedentary controls in women (6.5% 
versus 3.8%) and men (2.1% versus 1.1%). 
Black athletes are recognised to have greater prevalence of TWI than 
white athletes. In leads V1–V4 this may be interpreted as an ethnically 
determined normal physiological response to exercise.42 Papadakis et al. 
described ECG findings in 904 black athletes and compared them with 
1,819 white athletes, 119 black controls and 52 black patients with 
hypertrophic cardiomyopathy.45 TWI was seen in 22.8% of black athletes, 
predominantly confined to leads V1–V4, often with preceding J-point 
elevation and convex ST elevation (12.7%). 
Sheikh et al. compared ECGs of black and white adolescent athletes and 
showed a higher prevalence of TWI in the black athletes (V1–V4, 14.3%).40 
More recently, Mango et al. raised awareness that premature ventricular 
beats occurred more frequently in low QRS voltage among Olympic 
athletes.46 Such anomalies may be suggestive of underlying pathology 
particularly in subtle cases of myocarditis. 






•  Usually normal size but can have ventricular dilatation, 
     particularly endurance athletes (grey zone 60–65 mm) 
•   Usually normal but can have mildly reduced EF, usually 
     endurance athletes. Grey zone EF 45–50%. 
•   Usually normal LVWT but can be increased:
         •  Black men ≤15 mm
         •  Black women ≤12 mm
         •  White men ≤13 mm
         •  White women ≤11 mm
•   Regional wall motion abnormality
•   Ventricular dilatation or mildly reduced EF not in
     keeping with sports participation type and amount
•   LVWT exceeding that for ethnicity/sex
•   Inability to augment EF >11% or achieve peak
     exercise EF of >63% is more in keeping with DCM
     rather than athletic adaptation
•   White athletes TWI V1–V2
•   Black athletes TWI V1–V4, often accompanied
     by J point ST elevation
•   Lateral TWI
•   ST depression
•   Q waves
•   Arrhythmia at rest or on exertion
LGE in pathological distribution with other clinical
investigations/history suspicious of pathology 
LGE may be a feature in healthy athletes: patchy fibrosis in
basal inferior lateral wall has been seen in masters athletes
Figure 2: Factors that Can Help Differentiate Physiological Adaptation from Pathological Change in Athletes
CMR = cardiac MRI; DCM = dilated cardiomyopathy; EF = ejection fraction; LGE = late gadolinium enhancement; LVWT = left ventricular wall thickness; TWI = T wave inversion.
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Table 1. Summary of Recent Return to Training Consensus Statements 
in Athletes with Confirmed or Suspected COVID-19
COVID-19 Symptoms COVID-19 Test Result Recommendations
Exercise in the SARS-CoV-2 
era22
Positive Positive • Self-isolate 7–14 days
• No exercise until symptom-free for 7 days
• Consider troponin and CRP
• If troponin positive, consider ECG; CMR; TTE; ECG monitoring
• If no cardiac involvement, graduated return to play after 
symptom-free for 7 days
• Consider repeat COVID-19 testing to ensure negative status 
prior to return to training
Negative Positive • No exercise for 7 days from test result
• If symptom-free at day 7 then graduated return to training
• Consider repeat COVID-19 testing to ensure negative status 
prior to return to training
Positive Negative • Manage as coryzal symptoms
• If high index of suspicion for COVID-19 then re-test or treat as 
though COVID-19 positive
A game plan for the 
resumption of sport and 
exercise after COVID-19 
Infection17
Negative Negative • No limitations
Negative Positive • No exercise for 14 days then slow monitored resumption
Mild – not hospitalised Positive • Following symptoms, no exercise for 14 days
• Before resumption of activity 12-lead ECG, TTE, high 
sensitivity troponin and additional tests as guided by 
symptoms
Significant symptoms – hospitalised Positive • Troponin and cardiac investigations in hospital as needed
• If troponin/cardiac study abnormal then investigate for 
myocarditis
• If normal hospital cardiac investigations: no exercise for first 
14 days while asymptomatic; consider cardiac testing if not 
done in hospital; slow resumption of activity
Positive Negative • Consider following pathway as if COVID-19 positive
Return to sports after 
COVID-19 infection20
Negative Positive • No intense or competitive exercise for 14 days
• If symptom-free and normal ECG then return to full 
competitive sports
Positive Positive • Clinical investigations according to severity
• If no evidence of myocarditis then sports restriction for at 
least 2–4 weeks. Subsequent cardiology follow-up: if normal 
then return to full competitive sports. If abnormal and not in 
keeping with myocarditis then consider differential diagnosis
• If evidence of myocarditis then treat as per recognised 
guidelines
Positive Negative • Treat as COVID-19 positive






Moderate to Severe Symptoms (Hospitalised) 
with Confirmed/Suspected COVID-19
The resurgence of sport 
in the wake of COVID-19: 
cardiac considerations 
in competitive athletes21
• Focused medical history and physical 
examination
• Consider 12-lead ECG
• Further evaluation if above abnormal
• Focused medical history and physical 
examination
• 12-lead ECG
• Further evaluation if above abnormal 
(or ECG shows new changes 
compared with previous)
• Comprehensive evaluation to include blood biomarker, ECG, 
TTE, exercise testing, ECG monitoring
• In athletes with documented myocardial injury then 
comprehensive evaluation to include blood biomarker, ECG, 
TTE, exercise testing, ECG monitoring and CMR
Mild to Moderate Infection Complicated or Prolonged Infection
Graduated return to 
play guidance following 
COVID-19 infection19
• 10 rest days and at least 7 days symptom-free
• 7 days of graduated increase in exercise incrementing type of 
exercise, duration, heart rate max %
• Specialty review with advanced tests, such as cardiac biomarker blood 
tests, ECG, echocardiogram, exercise tolerance test, CMR
CMR = cardiac MRI; COVID-19 = coronavirus disease 2019; CRP = C-reactive protein; TTE = transthoracic echocardiography.





LV dilatation and dysfunction may be a feature of cardiac pathology, such 
as heart failure or myocarditis, due to COVID-19. Overlap between 
physiological change and a pathological process may exist in a subset of 
athletes, particularly endurance athletes. This assessment of LV cavity 
size has been shown to be increased in athletes when compared to 
healthy controls.47 While athletes may demonstrate increased cavity 
dimensions, it is unusual for proportions to reach the pathological 
threshold, for example with dilated cardiomyopathy (DCM). However, 
studies have reported that cavity dilatation >60 mm can be seen in up to 
14% of male participants. This level of dilatation is more commonly seen in 
high capacity endurance sports, such as cycling.47,48
As with male athletes, it is unusual for LV cavity dimensions in female 
athletes to exceed normal limits. Pelliccia et al. studied 600 elite female 
athletes and found that an LV end diastolic dimension >54 mm was seen 
in 8% and >60 mm seen in 1%.49 Again, those with greater LV cavity 
diameter were more likely to be endurance athletes.
Left Ventricular Ejection Fraction 
Physiological adaptation may cause some athletes to exhibit a 
reduced ejection fraction that overlaps with pathological LV systolic 
dysfunction (ejection fraction 45–49%). This occurs in a minority of 
athletes, particularly from endurance sports. Abergel et al. showed 
that in a group of 286 elite cyclists, 147 (51.4%) demonstrated LV end 
diastolic dilatation (>60 mm) and of these 17 (11.6%) demonstrated 
reduced LVEF (<52%).50 More recently, Millar et al. reported that an 
improvement of 11% in ejection fraction from baseline using exercise 
stress echocardiography has the greatest discriminatory value in 
differentiating between grey-zone athletes and asymptomatic patients 
with DCM.51
Left Ventricular Wall Thickness
LV hypertrophy is a rare complication of acute myocarditis.52 Knowledge 
of physiological hypertrophy in athletes will be of use in differentiating 
physiological from pathological hypertrophy. Studies have shown that 
black male athletes have a greater mean maximal wall thickness than 
white athletes (11.3 mm versus 10 mm). It is uncommon for athletes to 
exceed the upper limit of normal wall thickness (12 mm in men and 11 mm 
in women).53 It is more common to see increased wall thickness in black 
athletes when compared to white athletes: LV wall thickness (LVWT) >12 
mm (18% black male athletes versus 4% white male athletes) and >15 mm 
(3% black male athletes versus 0% white male athletes). Physiological 
adaptation rarely causes LVWT >16 mm, irrespective of ethnicity.45,54,55A 
similar finding of increased LVWT is seen in black female athletes when 
compared to white female athletes. Studies have demonstrated LVWT 
>11 mm in 3% of black female athletes versus none in white female 
athletes (with no female athlete exceeding an LVWT of 13 mm).56–58 
Cardiac MRI 
CMR allows advanced assessment of tissue characterisation in addition to 
ventricular volume and function assessment. The presence of late 
gadolinium enhancement (LGE), indicating myocardial fibrosis, has been 
shown to be a predictor of mortality in those with myocarditis irrespective 
of ejection fraction.59,60 Normal CMR in those with suspected myocarditis 
correspond to a low annual major adverse event rate of 0.8% and a death 
rate of 0.3%.61 LGE distribution in acute myocarditis has been documented 
to predominantly have a subepicardial or mid-myocardial distribution.62 
Several studies have also reported myocardial fibrosis detected by LGE 
on CMR in athletes, with cohorts of master athletes showing patterns of 
non-ischaemic fibrosis.63–65 Further studies are needed to assess whether 
this finding in athletes represents a pathological manifestation of cardiac 
disease or a reflection of physiological stresses due to prolonged bouts of 
sports participation. 
Returning to Sport Post COVID-19: Guidance
Current recommendations for a return to sport following COVID-19 
infection are based on consensus. Some have advocated no participation 
in intense exercise or competitive sports for 14 days in those who are 
asymptomatic with a positive COVID-19 test and a normal ECG.20 The use 
of biomarkers, such as high sensitivity troponin, in asymptomatic people 
has also been recommended by some before a return to full training.18 A 
recent graduated return to play consensus statement describes 
implementation of a protocol following a 10-day rest period (with at least 
a 7-day symptom-free period).19 Here, activity duration, heart rate 
percentage and type of exercise is described with a goal of returning to 
normal training by day 7. It is widely agreed that athletes who have a 
complicated COVID-19 illness with cardiac symptoms or who have 
abnormal cardiac biomarker results require a more detailed cardiac 
assessment including ambulatory ECG monitoring, echocardiography and 
CMR.16–20 A summary of recent consensus guidelines on return to sports 
following confirmed or suspected COVID-19 is shown in Table 1. 
Cardiac Complications of COVID-19 
in Athletes: Returning to Sport
Myocarditis:66
• Consensus guidelines from the European Association of Preventative 
Cardiology (EAPC) were published in 2019, followed most recently by 
the European Society of Cardiology’s updated guidelines.67
• Exercise programmes should be restricted for 3–6 months.
• Resumption of training can be considered when LV systolic function 
Table 2. Risk Stratification of Those with Coronary Disease Prior to Sports Participation
Probability for Exercise-Induced Adverse Cardiac Events
Low Probability High Probability
• <70% stenosis of major coronary artery or <50% left main stem disease
• Ejection fraction ≥50% and no wall motion abnormality
• Normal age-adjusted exercise capacity
• Absence of inducible ischaemia on maximal exercise testing
• Absence of major ventricular tachyarrhythmias (non-sustained VT, frequent ventricular 
ectopic beats) at rest or during maximal stress testing.
• >70% stenosis of at least one major coronary artery or >50% left main stem disease
• Ejection fraction <50%
• Dyspnoea at low exercise intensity
• Exercise-induced ischaemia on maximal exercise testing
• Major ventricular tachyarrhythmias (non-sustained VT, frequent ventricular ectopic 
beats) at any time
• Dizziness or syncope on exertion
• High degree of myocardial scarring on CMR imaging
CMR = cardiac MRI; VT = ventricular tachycardia.
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has returned to normal range, serum biomarkers of myocardial injury 
have normalised and clinically relevant arrhythmias are absent on 
24-hour ECG monitoring and exercise test.
• Asymptomatic athletes with LGE should remain under annual clinical 
surveillance.
Pericarditis:66
• Athletes with pericarditis should not participate in competitive sports 
during the acute phase and can return following complete resolution 
of the active disease. Three months is considered an appropriate 
time period to ensure complete clinical and biochemical resolution 
but shorter periods of at least 1 month may be considered in selected 
mild cases that have prompt resolution. 
• Return to play is reasonable if serum biomarkers, LV function and 
rhythm monitoring (either 24-hour ECG or exercise ECG) are normal.
• Athletes with myocardial involvement should be treated with 
recommendations for myocarditis.
• Asymptomatic athletes with small pericardial effusion detected 
incidentally by imaging but without myopericarditis should not be 
restricted from sports participation. Periodic surveillance is 
advisable. 
Left ventricular dysfunction:66
• Athletes with DCM and mild LV dysfunction (EF ≥ 40%) who are 
asymptomatic or do not have a history of syncope or complex rhythm 
disturbance may compete in sports, with the exception of those 
where syncope may be associated with serious harm or death, such 
as motor racing, scuba diving and rock climbing. 
• Athletes with DCM should be advised not to engage in competitive 
sports if they are symptomatic or have one of the following: LV 
ejection fraction <40%; extensive LGE on CMR; frequent complex 
ventricular tachyarrhythmias on monitoring or a history of 
unexplained syncope. 
MI:68
• Athletes with proven coronary artery disease as documented by an 
earlier clinical event, CT scan or coronary angiography should be 
assessed on an individual basis. The aim is to risk stratify the 
likelihood of an exercise-induced cardiac event (Table 2). Athletes 
considered as having a low probability for cardiac events are eligible 
for most sports although restrictions may apply on an individual basis 
for certain sports with the highest cardiovascular demand, such as 
extreme power and endurance disciplines.
Conclusion
This review has highlighted recent consensus statements for the return to 
sports participation following confirmed or suspected COVID-19. 
An understanding of the cardiovascular complications of COVID-19 
together with an overview of investigation findings that can help 
differentiate physiology from pathology in athletes will benefit clinical 
decision-making. 
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